Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant

Cost-effective, and accessible vaccines are needed for mass immunization to control the ongoing coronavirus disease 2019 (COVID-19), especially in low- and middle-income countries (LMIC). A plant-based vaccine is an attractive technology platform since the recombinant proteins can be easily produced...

Descripción completa

Detalles Bibliográficos
Autores principales: Phoolcharoen, Waranyoo, Shanmugaraj, Balamurugan, Khorattanakulchai, Narach, Sunyakumthorn, Piyanate, Pichyangkul, Sathit, Taepavarapruk, Pornnarin, Praserthsee, Wanlapa, Malaivijitnond, Suchinda, Manopwisedjaroen, Suwimon, Thitithanyanont, Arunee, Srisutthisamphan, Kanjana, Jongkaewwattana, Anan, Tomai, Mark, Fox, Christopher B., Taychakhoonavudh, Suthira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027959/
https://www.ncbi.nlm.nih.gov/pubmed/36963999
http://dx.doi.org/10.1016/j.vaccine.2023.03.027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027959/
https://www.ncbi.nlm.nih.gov/pubmed/36963999
http://dx.doi.org/10.1016/j.vaccine.2023.03.027

Ejemplares similares